Co-founded by CRISPR pioneer Jennifer Doudna, Mammoth Biosciences is developing next-generation CRISPR systems beyond Cas9, including ultracompact Cas14 and Casf proteins. The company has a dual focus on in vivo gene editing therapeutics and CRISPR-based point-of-care diagnostics (DETECTR platform).